Navigation Links
Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Proteolix, Inc. announced today that data from two Phase 1 clinical studies using intravenous carfilzomib (PR-171) are to be presented at the 2007 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December 8-10, 2007. Carfilzomib is a potent and selective proteasome inhibitor currently being investigated for the treatment of multiple myeloma, lymphoma and solid tumors.

Robert Z. Orlowski, M.D., Ph.D., of the University of Texas, M.D. Anderson Cancer Center, and Melissa Alsina, M.D., of the H. Lee Moffitt Cancer Center and Research Institute, will be presenting data from two Phase 1 clinical studies in relapsed and refractory hematologic malignancies on Monday, December 10 beginning at 11:00 am and 11:30 am EST, respectively, in a session entitled "Novel Therapies in Relapsed Myeloma." Additional information about the 2007 ASH Annual Meeting can be found on the ASH website at http://www.hematology.org/meetings/2007.

"We are very pleased that carfilzomib can be dosed on a consecutive-day schedule in humans, as was predicted by animal studies," said Susan M. Molineaux, Ph.D., President and CEO of Proteolix. "These early results showing single-agent activity in myeloma indicate the potential of this product candidate to help persons afflicted with the disease. We look forward to data throughout 2008 from ongoing Phase 1b and 2 studies in multiple myeloma, lymphoma and solid tumors."

About Proteolix

Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancer and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in different types of cancer, Proteolix is developing next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this target class. Proteolix is headquartered in South San Francisco. For more information, please visit the Company's website at http://www.proteolix.com.

Contact: Stephen Brady, Executive Director of Business and Legal Affairs,

650-266-2621.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Cranbury, NJ (PRWEB) , ... January 17, 2017 ... ... television personality, and breast cancer survivor Sandra Lee as keynote speaker for the ... Miami Beach, Florida. , In making the announcement, PER® president, Phil Talamo, said, ...
(Date:1/17/2017)... York, NY (PRWEB) , ... January 17, 2017 ... ... Inc. Magazine’s fastest-growing private companies and ranked among the top US security companies ... Board of Directors. This announcement brings a year-long independent board nomination process ...
(Date:1/17/2017)... ... 17, 2017 , ... Today, FloSports , a global leader in live ... as part of a long-term extension of their media partnership. The partnership, which began ... of the sport’s premier events exclusively on FloWrestling.com as well as usage of the ...
(Date:1/16/2017)... ... January 17, 2017 , ... ... Pain, an internationally recognized leader in the fast-casual category, announces a hearty and ... the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, ...
(Date:1/16/2017)... ... January 16, 2017 , ... California Southern University has named Dr. Steven ... Board of Trustees and as a core faculty member, teaching master’s and doctoral courses ... of psychology at Pepperdine University, where he earned his Doctor of Psychology degree in ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Future published a Half Cooked Research Report on Endoscopy Devices Market. ... million during the period 2016 to 2022 from USD 28.7 million ... ... as a swiftly growing market and expected to grow at a ... various regions.  The increasing growth in endoscopy procedures is influencing the ...
(Date:1/17/2017)... 17, 2016  Attorney Advertising -- Bronstein, Gewirtz & Grossman, ... Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... and assist the investigation by visiting the firm,s site: ... certain of its officers and/or directors have violated Sections 10(b) ... ...
(Date:1/17/2017)... 17, 2017  In a letter to President-elect ... Jenkins outlines AARP,s priorities for Americans age 50 ... access to affordable health care coverage, and lowering the ... Jenkins writes to President-elect Trump that "Our nearly 38 ... on you to protect their Medicare and Social Security ...
Breaking Medicine Technology: